Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond ...
Please provide your email address to receive an email when new articles are posted on . Newer eGFR calculations that do not consider race show a link between kidney function and dementia. Equations ...
Dr. Nicolas Girard discussed the current treatment options for patients with EGFR-mutant lung cancer, including emerging combination regimens. Current treatment options for EGFR-mutant lung cancer ...
Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.
EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy, patients may have oligometastatic ...
Treatment landscape of EGFR-mutant non–small cell lung cancer has evolved in the most recent years. In the metastatic setting, with combination approaches tested in first-line, whereas in the ...
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study The Oncology Grand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results